Hedge Funds Weigh In On Timber Pharmaceuticals News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Hedge funds weigh in on timber pharmaceuticals. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Hedge Funds Weigh In On Timber Pharmaceuticals Today - Breaking & Trending Today

Timber Pharmaceuticals' (TMBR) "Buy" Rating Reiterated at HC Wainwright

Timber Pharmaceuticals (NYSE:TMBR – Get Rating)‘s stock had its “buy” rating reiterated by HC Wainwright in a research note issued on Monday, Benzinga reports. They currently have a $11.00 price objective on the stock. HC Wainwright also issued estimates for Timber Pharmaceuticals’ Q1 2024 earnings at ($0.49) EPS, Q2 2024 earnings at ($0.42) EPS, Q3 […] ....

Vanguard Group Inc , York Mellon Corp , News Ratings For Timber Pharmaceuticals Daily , Timber Pharmaceuticals , Hedge Funds Weigh In On Timber Pharmaceuticals , Timber Pharmaceuticals Inc , Timber Pharmaceuticals Trading , Renaissance Technologies , Get Rating , New York Mellon Corp , Vanguard Group , Timber Pharmaceuticals Daily , Nyse Tmbr , Reiterated Rating , Hc Wainwright ,

Timber Pharmaceuticals (NYSE:TMBR) Shares Down 1.8%

Timber Pharmaceuticals, Inc. (NYSE:TMBR – Get Rating)’s share price traded down 1.8% during trading on Monday . The company traded as low as $1.65 and last traded at $1.67. 17,821 shares traded hands during mid-day trading, a decline of 98% from the average session volume of 1,067,059 shares. The stock had previously closed at $1.70. […] ....

Timber Pharmaceuticals , Timber Pharmaceuticals Stock Performance , Timber Pharmaceuticals Inc , Timber Pharmaceuticals Company Profile , Hedge Funds Weigh In On Timber Pharmaceuticals , York Mellon Corp , Vanguard Group Inc , Renaissance Technologies , News Ratings For Timber Pharmaceuticals Daily , Get Rating , New York Mellon Corp , Vanguard Group , Timber Pharmaceuticals Daily , Nyse Tmbr ,